Abstract
Ibrutinib (PCI-32765), marketed under the trade name IMBRUVICA, is a first-in-class irreversible inhibitor drug of Bruton tyrosine kinase (BTK). In th......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
